The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance
Open accessAbstract
Esophageal adenocarcinoma (EAC) has a poor outcome, and targeted therapy trials have thus far been disappointing owing to a lack of robust stratification methods. Whole-genome sequencing (WGS) analysis of 129 cases demonstrated that this is a heterogeneous cancer dominated by copy number alterations with frequent large-scale rearrangements. Co-amplification of receptor tyrosine kinases (RTKs) and/or downstream mitogenic activation is almost ubiquitous; thus tailored combination RTK inhibitor (RTKi) therapy might be required, as we demonstrate in vitro. However, mutational signatures showed three distinct molecular subtypes with potential therapeutic relevance, which we verified in an independent cohort (n = 87): (i) enrichment for BRCA signature with prevalent defects in the homologous recombination pathway; (ii) dominant T>G mutational pattern associated with a high mutational load and neoantigen burden; and (iii) C>A/T mutational pattern with evidence of an aging imprint. These subtypes could be ascertained using a clinically applicable sequencing strategy (low coverage) as a basis for therapy selection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
A global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
A method and server for predicting damaging missense mutations.
Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., & Sunyaev, S. R. (2010) · Nature Methods · doi:10.1038/nmeth0410-248 · Cited by 13,194
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Self-citationThe cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche
Sato, T., Vries, R. G., Snippert, H. J., van de Wetering, M., Barker, N., Stange, D. E., van Es, J. H., Abo, A., Kujala, P., Peters, P. J., et al. (2009) · Nature · doi:10.1038/nature07935 · Cited by 7,204
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Kumar, P., Henikoff, S., & Ng, P. C. (2009) · Nature Protocols · doi:10.1038/nprot.2009.86 · Cited by 6,521
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., Van de Velde, C. J. H., Nicolson, M., Scarffe, J. H., Lofts, F. J., Falk, S. J., Iveson, T. J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055531 · Cited by 6,334
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking
Wilkerson, M. D., & Hayes, D. N. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq170 · Cited by 5,669
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
van Hagen, P., Hulshof, M. C. C. M., van Lanschot, J. J. B., Steyerberg, E. W., Henegouwen, M. I. V. B., Wijnhoven, B. P. L., Richel, D. J., Nieuwenhuijzen, G. A. P., Hospers, G. A. P., Bonenkamp, J. J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112088 · Cited by 5,521
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Mermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. L., Beroukhim, R., & Getz, G. (2011) · Genome Biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,550
Genomic classification of cutaneous melanoma
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.044 · Cited by 3,151
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642 · cited 2×
“The structural variant-based classification was used to annotate unstable, stable, locally rearranged and scattered genomes as previously described [11], but with different cut-offs for stable and unstable genomes, to account for the different genomic instability landscape in EAC compared to pancreatic cancer: genomes…”
Self-citationProspective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., Middleton, G., Daniel, F., Oates, J., & Norman, A. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa073149 · Cited by 2,285
(2015) · doi:10.1093/bioinformatics/btv710 · Cited by 2,234
Pan-cancer patterns of somatic copy number alteration
Zack, T. I., Schumacher, S. E., Carter, S. L., Cherniack, A. D., Saksena, G., Tabak, B., Lawrence, M. S., Zhang, C.-Z., Wala, J., Mermel, C. H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2760 · Cited by 1,870
Schulze, K., Imbeaud, S., Letouzé, E., Alexandrov, L. B., Calderaro, J., Rebouissou, S., Couchy, G., Meiller, C., Shinde, J., Soysouvanh, F., et al. (2015) · Nature Genetics · doi:10.1038/ng.3252 · Cited by 1,803
Strelka: accurate somatic small-variant calling from sequenced tumor–normal sample pairs
Saunders, C. T., Wong, W. S. W., Swamy, S., Becq, J., Murray, L. J., & Cheetham, R. K. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts271 · Cited by 1,635
Liu, Q., Guntuku, S., Cui, X.-S., Matsuoka, S., Cortez, D., Tamai, K., Luo, G., Carattini-Rivera, S., DeMayo, F., Bradley, A., et al. (2000) · Genes & Development · doi:10.1101/gad.14.12.1448 · Cited by 1,625
Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor
McLaren, W., Pritchard, B., Rios, D., Chen, Y., Flicek, P., & Cunningham, F. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq330 · Cited by 1,586
The Life History of 21 Breast Cancers
Nik-Zainal, S., Van Loo, P., Wedge, D. C., Alexandrov, L. B., Greenman, C. D., Lau, K. W., Raine, K., Jones, D., Marshall, J., Ramakrishna, M., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.023 · Cited by 1,443
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C. L., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70228-1 · Cited by 1,442
Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378
Emerging landscape of oncogenic signatures across human cancers
Ciriello, G., Miller, M. L., Aksoy, B. A., Senbabaoglu, Y., Schultz, N., & Sander, C. (2013) · Nature Genetics · doi:10.1038/ng.2762 · Cited by 1,378
Genomic spectra of biliary tract cancer
Nakamura, H., Arai, Y., Totoki, Y., Shirota, T., Elzawahry, A., Kato, M., Hama, N., Hosoda, F., Urushidate, T., Ohashi, S., et al. (2015) · Nature Genetics · doi:10.1038/ng.3375 · Cited by 1,284
Allele-specific copy number analysis of tumors
Van Loo, P., Nordgard, S. H., Lingjærde, O. C., Russnes, H. G., Rye, I. H., Sun, W., Weigman, V. J., Marynen, P., Zetterberg, A., Naume, B., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009843107 · Cited by 1,226
Di Leonardo, A., Linke, S. P., Clarkin, K., & Wahl, G. M. (1994) · Genes & Development · doi:10.1101/gad.8.21.2540 · Cited by 1,215
Boeva, V., Popova, T., Bleakley, K., Chiche, P., Cappo, J., Schleiermacher, G., Janoueix-Lerosey, I., Delattre, O., & Barillot, E. (2012) · Bioinformatics · doi:10.1093/bioinformatics/btr670 · Cited by 1,007
Allum, W. H., Stenning, S. P., Bancewicz, J., Clark, P. I., & Langley, R. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.2083 · Cited by 989
Non-coding recurrent mutations in chronic lymphocytic leukaemia
Puente, X. S., Beà, S., Valdés-Mas, R., Villamor, N., Gutiérrez-Abril, J., Martín-Subero, J. I., Munar, M., Rubio-Pérez, C., Jares, P., Aymerich, M., et al. (2015) · Nature · doi:10.1038/nature14666 · Cited by 829
Lundegaard, C., Lamberth, K., Harndahl, M., Buus, S., Lund, O., & Nielsen, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn202 · Cited by 808
Trans-ancestry mutational landscape of hepatocellular carcinoma genomes
Totoki, Y., Tatsuno, K., Covington, K. R., Ueda, H., Creighton, C. J., Kato, M., Tsuji, S., Donehower, L. A., Slagle, B. L., Nakamura, H., et al. (2014) · Nature Genetics · doi:10.1038/ng.3126 · Cited by 781
Dulak, A. M., Stojanov, P., Peng, S., Lawrence, M. S., Fox, C., Stewart, C., Bandla, S., Imamura, Y., Schumacher, S. E., Shefler, E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2591 · Cited by 735
Genetic landscape of esophageal squamous cell carcinoma
Gao, Y.-B., Chen, Z.-L., Li, J.-G., Hu, X.-D., Shi, X.-J., Sun, Z.-M., Zhang, F., Zhao, Z.-R., Li, Z.-T., Liu, Z.-Y., et al. (2014) · Nature Genetics · doi:10.1038/ng.3076 · Cited by 694
Incidence of Adenocarcinoma of the Esophagus Among White Americans by Sex, Stage, and Age
Brown, L. M., Devesa, S. S., & Chow, W.-H. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn211 · Cited by 690
Essential role of BETA2/NeuroD1 in development of the vestibular and auditory systems
Liu, M., Pereira, F. A., Price, S. D., Chu, M.-J., Shope, C., Himes, D., Eatock, R. A., Brownell, W. E., Lysakowski, A., & Tsai, M.-J. (2000) · Genes & Development · doi:10.1101/gad.840500 · Cited by 625
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
Van Cutsem, E., Bang, Y.-J., Feng-yi, F., Xu, J. M., Lee, K.-W., Jiao, S.-C., Chong, J. L., López-Sanchez, R. I., Price, T., Gladkov, O., et al. (2015) · Gastric Cancer · doi:10.1007/s10120-014-0402-y · Cited by 608
Therapeutic opportunities within the DNA damage response
Pearl, L. H., Schierz, A. C., Ward, S. E., Al-Lazikani, B., & Pearl, F. M. G. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3891 · Cited by 587
Oza, A. M., Cibula, D., Benzaquen, A. O., Poole, C., Mathijssen, R. H. J., Sonke, G. S., Colombo, N., Špaček, J., Vuylsteke, P., Hirte, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71135-0 · Cited by 547
Non-coding recurrent mutations in chronic lymphocytic leukaemia
Puente, X. S., Beà, S., Valdés-Mas, R., Villamor, N., Gutiérrez-Abril, J., Martín-Subero, J. I., Munar, M., Rubio-Pérez, C., Jares, P., Aymerich, M., et al. (2016) · Nature · doi:10.1038/nature18910 · Cited by 546
Criteria for Inference of Chromothripsis in Cancer Genomes
Korbel, J. O., & Campbell, P. J. (2013) · Cell · doi:10.1016/j.cell.2013.02.023 · Cited by 538
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors
Shen, J., Peng, Y., Wei, L., Zhang, W., Yang, L., Lan, L., Kapoor, P., Ju, Z., Mo, Q., Shih, I.-M., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0849 · Cited by 522 · cited 3×
“For the DDR impaired profile we hypothesised that PARPi, with or without a DNA-damaging agent such as Topotecan, might be beneficial [31, 41, 42].”
Comparative analysis of RNA sequencing methods for degraded or low-input samples
Adiconis, X., Borges-Rivera, D., Satija, R., DeLuca, D. S., Busby, M. A., Berlin, A. M., Sivachenko, A., Thompson, D. A., Wysoker, A., Fennell, T., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2483 · Cited by 503
Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle.
Watanabe, N., Broome, M., & Hunter, T. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07180.x · Cited by 450
Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes
Tubio, J. M. C., Li, Y., Ju, Y. S., Martincorena, I., Cooke, S. L., Tojo, M., Gundem, G., Pipinikas, C. P., Zamora, J., Raine, K., et al. (2014) · Science · doi:10.1126/science.1251343 · Cited by 412
Self-citationOrdering of mutations in preinvasive disease stages of esophageal carcinogenesis
the OCCAMS Consortium, Weaver, J. M. J., Ross-Innes, C. S., Shannon, N., Lynch, A. G., Forshew, T., Barbera, M., Murtaza, M., Ong, C.-A. J., Lao-Sirieix, P., et al. (2014) · Nature Genetics · doi:10.1038/ng.3013 · Cited by 348
Self-citationWatkins, J. A., Irshad, S., Grigoriadis, A., & Tutt, A. N. (2014) · Breast Cancer Research · doi:10.1186/bcr3670 · Cited by 327
SomaticSignatures: inferring mutational signatures from single-nucleotide variants
Gehring, J. S., Fischer, B., Lawrence, M., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv408 · Cited by 307
Copynumber: Efficient algorithms for single- and multi-track copy number segmentation
Nilsen, G., Liestøl, K., Van Loo, P., Moen Vollan, H. K., Eide, M. B., Rueda, O. M., Chin, S.-F., Russell, R., Baumbusch, L. O., Caldas, C., et al. (2012) · BMC Genomics · doi:10.1186/1471-2164-13-591 · Cited by 303
Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis
Nones, K., Waddell, N., Wayte, N., Patch, A.-M., Bailey, P., Newell, F., Holmes, O., Fink, J. L., Quinn, M. C. J., Tang, Y. H., et al. (2014) · Nature Communications · doi:10.1038/ncomms6224 · Cited by 273
Self-citationPoint mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia
Osato, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207779 · Cited by 268
Chantrill, L. A., Nagrial, A. M., Watson, C., Johns, A. L., Martyn-Smith, M., Simpson, S., Mead, S., Jones, M. D., Samra, J. S., Gill, A. J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0426 · Cited by 238
MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
Bridges, K. A., Hirai, H., Buser, C. A., Brooks, C., Liu, H., Buchholz, T. A., Molkentine, J. M., Mason, K. A., & Meyn, R. E. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0650 · Cited by 237
Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.
Wang, Y., Li, J., Booher, R. N., Kraker, A. J., Lawrence, T. S., Leopold, W. R., & Sun, Y. (2001) · PubMed · Cited by 210
Le Tallec, B., Millot, G. A., Blin, M. E., Brison, O., Dutrillaux, B., & Debatisse, M. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.07.003 · Cited by 188
A mutational signature in gastric cancer suggests therapeutic strategies
Alexandrov, L. B., Nik-Zainal, S., Siu, H. C., Leung, S. Y., & Stratton, M. R. (2015) · Nature Communications · doi:10.1038/ncomms9683 · Cited by 185
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
Cunningham, D., Okines, A. F. C., & Ashley, S. (2010) · New England Journal of Medicine · doi:10.1056/nejmc0911925 · Cited by 164
A Simple Model-Based Approach to Inferring and Visualizing Cancer Mutation Signatures
Shiraishi, Y., Tremmel, G., Miyano, S., & Stephens, M. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005657 · Cited by 121
Verhagen, C. V. M., de Haan, R., Hageman, F., Oostendorp, T. P. D., Carli, A. L. E., O’Connor, M. J., Jonkers, J., Verheij, M., van den Brekel, M. W. M., & Vens, C. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.03.028 · Cited by 115
An update on PARP inhibitors for the treatment of cancer
Hall, M., & Benafif, S. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s30793 · Cited by 112
Agarwal, M. L., Agarwal, A. M., Taylor, W. R., Chernova, O. B., Sharma, Y., & Stark, G. R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14775 · Cited by 110
A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress
Brooks, K. M., Oakes, V., Edwards, B., Ranall, M. V., Leo, P., Pavey, S. J., Pinder, A., Beamish, H., Mukhopadhyay, P., Lambie, D., et al. (2012) · Oncogene · doi:10.1038/onc.2012.72 · Cited by 103
Liu, D. S. H., Read, M. D., Cullinane, C. M., Azar, W. J., Fennell, C. M., Montgomery, K. G., Haupt, S., Haupt, Y., Wiman, K. G., Duong, C. P., et al. (2015) · Gut · doi:10.1136/gutjnl-2015-309770 · Cited by 94
Chk1 and Wee1 control genotoxic-stress induced G2–M arrest in melanoma cells
Vera, J., Raatz, Y., Wolkenhauer, O., Kottek, T., Bhattacharya, A., Simon, J. C., & Kunz, M. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.01.020 · Cited by 48
Schulte, I., Batty, E. M., Pole, J. C. M., Blood, K. A., Mo, S., Cooke, S. L., Ng, C. K. Y., Howe, K., Chin, S., Brenton, J. D., et al. (2012) · BMC Genomics · doi:10.1186/1471-2164-13-719 · Cited by 41
Self-citationPaterson, A., O’Donovan, M., Provenzano, E., Murray, L., Coleman, H. G., Johnson, B. T., McManus, D. T., Novelli, M. R., Lovat, L. B., & Fitzgerald, R. C. (2012) · The Journal of Pathology · doi:10.1002/path.4044 · Cited by 40
Self-citation(2015) · Europe PMC (PubMed Central) · Cited by 39
Paterson, A., Weaver, J. M. J., Eldridge, M., Tavaré, S., Fitzgerald, R. C., & Edwards, P. A. (2015) · BMC Genomics · doi:10.1186/s12864-015-1685-z · Cited by 31
Self-citationTitration of signalling output: insights into clinical combinations of MEK and AKT inhibitors
Stewart, A., Thavasu, P., Bono, J. S. D., & Banerji, U. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv188 · Cited by 23
Cited by
Maftools: efficient and comprehensive analysis of somatic variants in cancer
Mayakonda, A., Lin, D.-C., Assenov, Y., Plass, C., & Koeffler, H. P. (2018) · Genome Research · doi:10.1101/gr.239244.118 · Cited by 4,935
Smyth, E. C., Lagergren, J., Fitzgerald, R. C., Lordick, F., Shah, M. A., Lagergren, P., & Cunningham, D. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.48 · Cited by 1,012
Self-citationComparative Molecular Analysis of Gastrointestinal Adenocarcinomas
Liu, Y., Sethi, N. S., Hinoue, T., Schneider, B. G., Cherniack, A. D., Sanchez-Vega, F., Seoane, J. A., Farshidfar, F., Bowlby, R., Islam, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.010 · Cited by 615
The Epidemiology of Esophageal Adenocarcinoma
Coleman, H. G., Xie, S.-H., & Lagergren, J. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.07.046 · Cited by 549
Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer
Janjigian, Y. Y., Sanchez-Vega, F., Jonsson, P., Chatila, W. K., Hechtman, J. F., Ku, G. Y., Riches, J. C., Tuvy, Y., Kundra, R., Bouvier, N., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0787 · Cited by 375
Metadata
- Authors
- the Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium, Secrier, M., Li, X., de Silva, N., Eldridge, M. D., Contino, G., Bornschein, J., MacRae, S., Grehan, N., O'Donovan, M., Miremadi, A., Yang, T.-P., Bower, L., Chettouh, H., Crawte, J., Galeano-Dalmau, N., Grabowska, A., Saunders, J., Underwood, T., Waddell, N., Barbour, A. P., Nutzinger, B., Achilleos, A., Edwards, P. A. W., Lynch, A. G., Tavaré, S., & Fitzgerald, R. C.
- Venue
- Nature Genetics
- Published
- 2016-09-05
- Volume
- 48
- Issue
- 10
- Pages
- 1131-1141
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2490318515
- Cited by
- 405
- References
- 87
- FWCI
- 47.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.